Frequently asked questions


How does genomic testing differ from genetic testing?

Genetic testing detects hereditary (mainly inherited from parents) alterations in DNA while genomic testing detects acquired (over the course of a lifetime) alterations in DNA as well as measuring how much each gene is translated into proteins (RNA expression). Acquired alterations and differences in expression are thought to be responsible for the majority of cancers and may impact tumor growth, spread, and response to therapy.

What is OmiCure?

OmiCure provides a service that helps clinicians choose a personalized treatment.

OmiCure provides detailed information on whether your cancer profile contains genetic mutations that influence various treatment modalities.

Based on the result, we enable your oncologist to plan a personalized treatment for you.

You will be provided information on whether there is a treatment option in the world that is specially customized for your particular type of tumor. This treatment can be either a marketed drug or an innovative drug in clinical trial stage.

It is important to also know which treatments may not be effective, as you may be able to avoid unnecessary suffering and costs.

Although the availability of specific therapies cannot be guaranteed and is dependent on each individual cancer, our platform provides you with an up-to-date knowledge of what may be available for you.

The answer is often to continue the current treatment strategy and to not modify it. Because even in this age of targeted treatments, surgical removal is still the most effective method, and current radiotherapies and chemotherapies, as well as their combinations, are often successful. It is of utmost importance to have an oncologist help you to decide how to use the options provided based on molecular information.

OmiCure cannot assess whether a drug is appropriate, or gauge a patient’s ability to respond to any specific medication.
Patients should not look to the test for medical advice or to make treatment decisions on their own; instead, they should only use the information to guide discussions with their health care provider

What results can I expect?

Based on your personal results, your oncologist may propose a targeted therapy.

It may also be the case that with the help of OmiCure, the physician will avoid to use a drug that he or she would have otherwise proposed due to expected inefficacy. Therefore you do not have to loose time time in your fight against cancer and suffer unnecessary adverse events from an ineffective therapy.

The doctor may propose to continue the same therapy in the same oncology center, using traditional treatments or drugs in clinical trial stage.

Or, it may happen that you will be advised to participate in a clinical trial conducted in another oncology center (within your country or abroad), in which an active substance is evaluated that was specifically developed for tumors containing a gene mutation that your tumor also contains.

It can happen that we detect no mutations in any gene, or any alteration of gene expression, which does not mean that the test was unnecessary. As a matter of fact the absence of certain gene mutations may increase the efficacy of targeted treatments that influence other genes. On the other hand OmiCure saved time and repeated sampling.

If a new gene is discovered in the future, patients who know that their tumor tested negative for the previously known genes have a greater chance that the test of the new gene will be positive.

Patients for whom this information is already available may have access to this new treatment option in a shorter time.

OmiCure cannot assess whether a drug is appropriate, or gauge a patient’s ability to respond to any specific medication.
Patients should not look to the test for medical advice or to make treatment decisions on their own; instead, they should only use the information to guide discussions with their health care provider

Do the tests apply to all types of cancer?

At present, the OmiCure analysis is available for patients with all types of solid tumor, at all stages of the disease, and at any time during the treatment course. In many cases, patients will have already undergone surgery, radiation therapy, and/or one or more lines of chemotherapy.

When to do OmiCure Analysis?

OmiCure is ideally suited to patients who have resistant cancers, have failed standard-of-care treatment, or for patients with rare, incurable tumors for which there is no standard of care. A OmiCure Report can be obtained even after a patient’s tumor has progressed or while a patient is on a clinical trial or under treatment, especially if the physician is concerned that the clinical trial or treatment may not result in a durable response.

Does OmiCure conduct DNA or RNA sequencing test?

OmiCure itself does not focus on acquisition of genomic and proteomic data or next-generation sequencing (NGS) – 3rd party tumor profiling services perform these tests.

Many of these lab tests are covered by insurance.

Once we have your lab data, we analyze it against more than 20 million different drug-gene combinations to find the most advanced cancer treatment matching your tumor.

Why is the current standard of care not working?

Doctors and patients have traditionally relied upon “one-size-fits-all” treatments and procedures, including chemotherapy, radiation therapy and surgery, aimed largely at fighting a particular type or origin of cancer (e.g. breast, prostate, pancreatic, etc.) rather than target the unique nature of an individual patient’s cancer. This is despite one’s genotype having a profound influence on clinical responses to targeted anticancer therapies.

In fact, patients with the same cancer diagnosis not only are unlikely to share the same specific genetic variants but are also unlikely to have the same reactions to identical treatments. Thus, cancer must be viewed as a personal disease, with personalized treatments to best counteract the disease.

What is Precision Medicine?

Today, doctors are able to target the unique nature of an individual patient’s tumor by matching treatments at the molecular level, resulting in improved outcome.

A recent study found that patients with advanced cancers treated with the traditional or standard of care, which is based on their type or origin of cancer rather than their DNA tumor profile, had a mere 5% response rate to their treatment.

When patients with metastatic cancers were treated using a personalized approach, matching them at the molecular level, there was a 27% response rate.

This is personalized medicine.

And it is available now.

Does the report show hereditary cancer risks?

The OmiCure service is not considered to be a hereditary genetic testing service, since the gene mutations and the gene expression differences we detect are not typically congenital or inherited gene defects.

Defects of the genes that are related to the formation of tumors of epithelial origin are so-called somatic mutations, that is, mutations acquired during our life in our cells of our body, but not in our germ cells.

Therefore, test results do not show your or your relatives’ potential cancer risk. If you are interested in whether you or your relatives have a higher risk of cancer we can recommend you to genetic counseling services.